E-mail

E-mail a Wiley Online Library Link

Louis P. Garrison Jr., Deepa Lalla, Melissa Brammer, Joseph B. Babigumira, Bruce Wang and Edith A. Perez Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status Cancer 119

Version of Record online: 17 JUN 2013 | DOI: 10.1002/cncr.28196

Both immunohistochemistry and fluorescence in situ hybridization analyses of HER2 in breast cancer yield similar rates of concordance (92%) among expert pathologists. The majority of discordant cases can be adjudicated by review and discussion among pathologists.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH